SEVEN-YEAR FOLLOW-UP OF CLINICAL OSTEONECROSIS OF THE JAW CASES MANAGED WITH CGF AND PIEZOSURGERY

The disorder known as medication-related osteonecrosis of the jaw (MRONJ) is characterized by bone loss and necrosis in the jaw as a result of unfavourable drug interactions. The treatment strategies and results for MRONJ patients are assessed in this case series. Over a 60-month period, MRONJ patients were treated and observed as part of the retrospective study. Concentrated growth factor (CGF) and piezosurgery were used in the treatment. There are six clinical case reports in detail. According to the study, during the follow-up period, there was no recurrence of necrotic MRONJ lesions in any of the patients. Bone resections and the application of CGF were two surgical procedures that effectively promoted mucosal healing and stopped the disease's progression. The results highlight how difficult it is to manage MRONJ and how interdisciplinary thinking is essential. Patients' quality of life was enhanced and symptoms were effectively controlled with conservative measures and minimally invasive operations. Finding the best course of action is still difficult, which highlights the need for more study into complementary therapies and reconstructive surgery. For individualized and interdisciplinary care, a thorough preoperative evaluation and cooperation between dental, endocrinology, and cancer professionals are essential. In order to better understand MRONJ management and investigate novel therapeutic approaches, ongoing research is crucial. This will ultimately help patients who are coping with this challenging illness.